Circulating microRNAs are associated with variability in fasting blood glucose over 12-months and target pathways related to type 2 diabetes: A pilot study. (26th November 2021)

• Record Type: Journal Article
• Authors: Flowers, Elena; Allen, Isabel E; Kanaya, Alka M; Aouizerat, Bradley E
• Is Part Of: Diabetes & vascular disease research. Volume 18:Number 6(2021)
• Publication Date: 2021-11-26
• Subjects: microRNA -- diabetes -- fasting blood glucose -- biomarker; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/14791641211055837
• Languages: English
• ISSNs: 1479-1641

Abstract

Introduction: MicroRNAs (miRs) may be important regulators of risk for type 2 diabetes (T2D). Circulating miRs may provide information about which individuals are at risk for T2D. The purpose of this study was to assess longitudinal associations between circulating miR expression and variability in fasting blood glucose (FBG) and to identify miR-targeted genes and biological pathways. Methods: Variability in FBG was estimated using standard deviation from participants ( n = 20) in a previously completed yoga trial. Expression of 402 miRs was measured using hydrogel particle lithography. MirTarBase was used to identify mRNAs, and miRPathDB was used to identify pathways targeted by differentially expressed miRs. Results: Six circulating miRs (miR-192, miR-197, miR-206, miR-424, miR-486, and miR-93) were associated with variability in FBG and targeted 143 genes and 23 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Six mRNAs ( AKT1, CCND1, ESR1, FASN, SMAD7, and VEGFA ) were targeted by at least two miRs and four of those were located in miR-targeted KEGG pathways. Conclusions: Circulating miRs are associated with variability in FBG in individuals at risk for T2D. Further studies are needed to determine whether miRs may be prodromal biomarkers that can identify which individuals are at greatest risk to progress to T2D and which biological pathways underlie this risk.